The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that ...

– Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein ...

CSL Behring has made a name for itself manufacturing biologics and plasma, but its unveiling of a new R&D site—slated to be the company’s largest—is evidence of expanded development efforts. The new ...

KING OF PRUSSIA, Pa., June 20, 2023 /PRNewswire/ -- Global biotechnology leader CSL Behring today announced that the first patient has received U.S. Food and Drug Administration (FDA) approved ...

SAN FRANCISCO--(BUSINESS WIRE)--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage points, according to ...

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...

BRADLEY, Ill. (WLS) -- A strike has ended at CSL Behring in Kankakee County and union employees will be back Thursday. Management and union leaders reached a new three-year deal. Last week, more than ...

The FDA has accepted CSL Behring’s priority review application for a hemophilia B gene therapy, potentially fast-tracking the drug after a bumpy ride that included a clinical hold—and later, a lift.

KING OF PRUSSIA, Pa., May 6, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) ...